These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Memantine for treatment of moderate to severe Alzheimer's disease. Perras C Issues Emerg Health Technol; 2005 Mar; (64):1-4. PubMed ID: 15762015 [TBL] [Abstract][Full Text] [Related]
11. [Therapy of Alzheimer disease]. Kovács T Neuropsychopharmacol Hung; 2009 Mar; 11(1):27-33. PubMed ID: 19731816 [TBL] [Abstract][Full Text] [Related]
12. A responder analysis of memantine treatment in patients with Alzheimer disease maintained on donepezil. van Dyck CH; Schmitt FA; Olin JT; Am J Geriatr Psychiatry; 2006 May; 14(5):428-37. PubMed ID: 16670247 [TBL] [Abstract][Full Text] [Related]
13. Symptomatic treatments in Alzheimer's disease in 2016: a study from Memory centers in France. Hommet C; Novella JL; Auriacombe S; Vercelletto M; Berrut G; Belliard S; Desmidt T; Ceccaldi M Geriatr Psychol Neuropsychiatr Vieil; 2016 Sep; 14(3):274-86. PubMed ID: 27651009 [TBL] [Abstract][Full Text] [Related]
14. The treatment of Alzheimer's disease: the approach from a clinical specialist in the trenches. Hake AM Semin Neurol; 2002 Mar; 22(1):71-4. PubMed ID: 12170395 [TBL] [Abstract][Full Text] [Related]
15. Cognitive response to memantine in moderate to severe Alzheimer disease patients already receiving donepezil: an exploratory reanalysis. Schmitt FA; van Dyck CH; Wichems CH; Olin JT; Alzheimer Dis Assoc Disord; 2006; 20(4):255-62. PubMed ID: 17132970 [TBL] [Abstract][Full Text] [Related]
16. Does this patient have Alzheimer disease? Diagnosing and treating dementia. Messinger-Rapport BJ Cleve Clin J Med; 2003 Sep; 70(9):762, 764, 766-70 passim. PubMed ID: 14518571 [TBL] [Abstract][Full Text] [Related]
17. Benefits of combined cholinesterase inhibitor and memantine treatment in moderate-severe Alzheimer's disease. Gauthier S; Molinuevo JL Alzheimers Dement; 2013 May; 9(3):326-31. PubMed ID: 23110864 [TBL] [Abstract][Full Text] [Related]
18. Activities of daily living in moderate-to-severe Alzheimer disease: an analysis of the treatment effects of memantine in patients receiving stable donepezil treatment. Feldman HH; Schmitt FA; Olin JT; Alzheimer Dis Assoc Disord; 2006; 20(4):263-8. PubMed ID: 17132971 [TBL] [Abstract][Full Text] [Related]
19. [New options for the pharmacotherapy of Alzheimer disease after the approval of memantine? Re the article from DMW 8/2005]. Wellhöfer B Dtsch Med Wochenschr; 2006 Feb; 131(6):284. PubMed ID: 16463237 [No Abstract] [Full Text] [Related]
20. Time to Treatment Initiation in People With Alzheimer Disease: A Meta-Analysis of Randomized Controlled Trials. Tsoi KK; Hirai HW; Chan JY; Kwok TC J Am Med Dir Assoc; 2016 Jan; 17(1):24-30. PubMed ID: 26392193 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]